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CHAPTER:! 
INTRODUCTION 
Enzyme deficiency diseases 
Certain genetic disorders are manifested as enzyme 
deficiencies or defects. One of them is lysosomal overloading, 
which occurs in all inborn lysosomal disorders. In these 
disorders, the metabolic block is in intracellular digestion, 
which causes the intralysosomal accumulation of all complex 
molecules that require the deficient enzyme(s) for their 
degradation. Some such disorders are summarised in Table 1. 
Lysosomes of cells affected by such a lysosomal disorder are not 
only larger but also have a characteristic morphology different 
from that normally present in a given ceil type. During 
digestion of biological materials in the lysosomes, low molecular 
weight breakdown products diffuse across the lysosomal membrane 
and reach the cytoplasm where they can be reused for synthesis or 
be secreted. However, the slowly digestible or indigestible 
remnants of this digestive process remain in the lysosomes 
(1,2,3). It has been found that lysosomes are reused repeatedly 
in cellular digestive processess and during the life of a 
iysosome, indigestible residues continue to accumulate (4).This 
process can be demonstrated by offering indigestible material to 
lysosomes. Experimentally induced storage can be obtained -by 
allowing cells to ingest materials such as sucrose (5 ), dextran 
(6 ) metal colloids (7) and mannitol (8).Effective enzyme 
replacement is often problemmatic. In addition to problems of 
hypersensitivity reactions mounted against a foreign protein, the 
enzyme deficiency is often intracellular and possibly 
intralysosomal such that any thought of enzyme replacement must 
consider the multitude of physical barriers that will have to be 
crossed before therapy can be achieved. Also the enzyme, on 
reaching the intra-lysosomal compartment, would be rapidly 
degraded by hydrolytic enzymes present in the lysosomes. 
The potential of enzymes as theraputic agents has been 
recognised for over a century since Purdon in 1871 used certain 
proteolytic enzymes to inhibit bacterial infection during 
surgery. Sir Archibald Garrod in 1909 (9) first described the 
concept of inborn errors of metabolism, predicted the source as 
enzyme deficiencies and foresaw the potential of enzyme 
replacement therapy. The use of L-asparaginase in the treatment 
of acute lymphocytic leukemia (ALL) was first concieved by Kidd 
in 1953. Despite the wide spread potential of enzymes as thera-
peutic agents several limitations have militated against their 
successful use in medicine. 
(a) Until recently many enzymes, especially in pure form were 
not readily available. 
(b) Upon administration, enzymes as proteins are readily 
susceptible to rapid bioinactivation at 37 C or proteolytic 
degradation. 
(c) Enzymes as foreign proteins are highly immunogenic. 
(d) In the case of enzyme therapy for the treatment of lysosomal 
storage diseases (manifest as enzyme deficiencies) access to 
sites of substrate accumulation is limited. 
The development of modern techniques such as solid state 
protein synthesis and recombinant DNA synthesis for the 
production of animal or human gene product may alleviate the 
first limitation but problems of bioinactivation, immunogenicity. 
and site specific delivery remain. 
Michael Col ley and Brenda E Ryman (10 ) in 1976 conducted studies 
on model storage disease created in the liver of rats, due to the 
accumulatioh of the injected dextran. Dextran remains in the rat 
liver for extended periods of time due to the absence of 
dextranase in rats. The intravenous administration of dextrarase 
entrapped in liposomes produces a rapid decrease in the amount of 
dextran in the liver. Rahman and Coworkers have successfully 
removed Plutonium stored within liver lysosomes by administering 
a chelating agent within liposomes (11). 
Stability of enzymes 
Considerable evidence has accumulated in recent years 
Indicating that lysosomes play an Important role in the 
Intracellular digestion of materials taken up by endocytosis or 
segregated by autophagy. This view is based partly on the 
finding that lysosomes contain numerous hyaro lytic en2:ymes. Tneir 
concerted action is thought capable of extensively degrading 
natural constituents . Also a variety of observations, cctn 
biochemical and morphological, show that objects gaming access 
to lysosomes m ceils indeed suffer degradation m them. 
Some work has been carried out on modif Icatj.on of the 
enzymes, in order to make them more stable in vitro .iMarsha. 1 et 
ai have shown that covalent attachment of trypsin to dextran 
resulted in a modified trypsin which showed greater resistance 
than the native enzyme to inactivation by heat treatment, 
autodigestion, or denaturing agents, and was also more resistant 
to inhibitors. Intramolecular crosslinking of enzyme molecules 
by polysaccharide chains is considered to be responsible for the 
stabilization of the tertiary structure of the enzyme molecules 
in the conjugate (12). 
It is known that most lysosomal enzymies have hydro lytic 
activity and low pH optimum. They are stable at low pH in the 
presence of other lysosomal proteases, and almost all of them are 
glycoproteins. Some of the structural properties of the 
lysosomal enzymes are summarised in Table II. Goldstone and 
Koenlg (13) have suggested that a number of enzymes present in 
the kidney lysosomes are glycoproteins. The role of the sugar 
moieties on the lysosomal enzymes has not be successfully 
elucidated. A number of hypothesis have however been put forward 
to explain their presence. 
1) The carbohydrate residues may serve as recognition markers for 
the cellular components. 
2) The bulky carbohydrate moieties may be involved in the 
noncovalent attachment of lysosomal enzymes to lysosomal 
membranes or components. 
3) Recent studies have shown that glycoproteins are not easil/' 
acted upon by proteolytic enzymes and that they are resistant to 
digestion. This may be the reason why the lysosomal enzymes 
concentrated in a medium of low PH containing a number of 
proteolytic enzymes, escape attack by other similar enzymes and 
hence degradation. 
Macrophages, mannose receptors and receptor mediated endocytosis: 
The Reticuloendothetial system (RES or monocyte - macrophage 
system, as it is sometimes called) comprises a set of 
mononuclear phagocytic cells. 
These cells originate from precursors in the bone marrow, 
and enter the circulation as monocytes. They have a half life of 
about 72 hours and then they pass into various tissues where they 
differentiate into macrophages. The macrophages are a crucial 
component of the host defence system. They are involved in 
antibody responses via the processing and presentation of 
antigens, and are responsible for secreting factors which 
regulate the functions of lymphoid cells. Finally the macrophages 
are themselves effector cells which can acquire the capacity to 
destroy both pathogens as well as tumor cells. They are 
sometimes called the professional phagocytes and those most 
closely involved with this function are the Kupffer cells of the 
liver .They not only take up macromolecular substances such as 
liposomes, microspheres, and other drug delivery agents, but also 
proteins which appear to be taken up by receptor 'mediated 
endocytosis (14). 
Receptors: 
The macrophage membrane contains a number of receptors, 
including those for the Fc domain of IgG, for the complement and 
for the mannosy1/fucosy1 terminated glycoproteins. The mannose 
receptor is responsible for regulation of the extracellular 
levels of lysosomal hydrolases(15). 
It is a 175 K Dalton protein which binds sugars V7ith terminal 
mannose, fucose and N.Aoetylglucosamine. It is present on the 
macrophages from lung, liver and peritoneum of a variety of 
mammalian species including rats, rabbits and humansi (16,17,18). 
The presence of this receptor has also been reported on human 
placental cells (19). 
It is a recycling kind of a receptor (20) which binds 
ligands at neutral pH and at high extracel lulcir Ca+ ion 
2 
concentration, it then releases these ligands at the low 
intracellular Ca+ ion concentration and lysosomal pH (<6) to 
2 
recycle back to the surface (18 ). 
The presence of this receptor on the surface of macrophages 
seems to be closely regulated, while it is not present on the 
surface of circulating monocytes, it seems to be expressed upon 
monocyte - macrophage differenciation . The expression or this 
receptor can be increased by antiinflammatory steroids such as 
dexamethasone. and decreased by lympnokines (2;. ,22) . The 
mechanism for this is however, not known. 
The presence or this receptor on the surface or .oiacrcpnages 
has been repeatedly exploited for targettmg moiecu:es or drug 
carriers to the macrophages. Ghosh et ai (23 ) have iigated ?ara 
ammomannoside to the liposomal surface for targettmg liposome 
as well as encapsulated drugs specifically to the macrophages. 
Liposomes as drug carrier 
The therapeutic efficacy of drugs to combat a v/ide range of 
diseases is often diminished by their inability to reach the 
.diseased site at an appropriate dosage. To achieve a 
therapeutically relevent dose at the target tissue the amount of 
drug required often proves to be toxic to the normal tissue. To 
circumvent this problem several investigators have proposed the 
use of drug carriers. A variety of such carriers include 
liposomes, protein microspheres, cellular carriers and immune 
toxins . Because of obvious advantages (Protection of the 
drug/enzyme from hostile environment, targetting potential, non-
toxic nature, biodegradability, and the presence of a wide range 
of phospholipids which would allow for a great deal of 
flexibility in modelling them for therapy), the use of liposomes 
as drug/enzyme carriers has attracted a lot of attention. The 
targetting of the drug-carrier complex to the diseased tissue is 
however not so simple. There stand between the site of injection 
and the target tissue a number of physiological barriers, of 
which some are discussed here. 
The purpose of any -controlled drug delivery system Is to 
ensure the transit of the drug-carrier complex from the site of 
injection to the target tissues. 'Several different routes of 
administration are available: oral, intravenous, intraperitoneal 
subcutaneous etc. In most cases, however, the body's own 
vascular network is used. The lumen of the vasculature is 
circumscribed by a layer of endothelial cells which demarcate 
between the vascular and the extravascular compartments. Three 
major types of vascular endothelia are present. 
a) The continuous epithelia : Forms the tight blood brain barrier 
of the central nervous system (CNS). It is also found in the 
capillaries of the muscles, lung and bone marrow. 
b) The fenestrated epithelia : The cellular layer is penetrated 
by tranacellular circular openings (600-800 A) with an underlying 
continuous basement membrane. Found in the renal glomerulus, the 
endocrine glands and the intestinal mucosa. 
c) Sinusoidal epithelia : The vasculature has gaps upto thousands 
of Angstrom in diameter. It is found in the liver and the 
spleen. 
It is the sinusoidal capillaries that provide the escape 
route to the injected drug-carrier complex. Any injected drug is 
therefore routed through the liver and spleen. 
Another physiological barrier presents itself ir. the form of 
the reticuloendothelial system (RES) or monocyte-macrophage 
system as it is sometimes called. It is the bodv's disposal 
system for foreign particles and macromolecules, By scanning 
electron microscopic techniques it has been shown that Kupffer 
cells actually surround the channels of the liver sinusoids and 
are therefore in an ideal position to catch the passing 
particles. (24 ). They engulf not only the macromoiecular 
particles but also proteins which appear to be taken m by 
receptor mediated endocytotic mechanisms (25 j . A numcer of 
giycoprotems bearing a terminal mannose are taken u? by 
macrophages by this metnoa. 
The presence of mannosyi/fucosy1 specific recsptor en the 
macrophages has been exploited by a number of groups inc.uding 
ours to specifically target drug/macrophage activators to the 
macrophages . We have previously shown that coating of sugars, 
with terminal mannose, on the liposomes increases the uptake of 
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these liposomes by the Kupffer cells (23 ). SUV's which can 
escape the vasculature through the liver sinusoids can be 
targetted to the galactose receptor of the hepatocytes by 
ligating galactose on surface of these liposomes (23). Various 
Icinds of liposomes can be made using different methods. These 
include large unilamellar (LUV), multilamellar (MLV) and small 
unilamellar (SUV) vesicles. The drug/enzyme can either be 
encapsulated inside the aqueous phase of the liposomes or 
intercatated in the lipid bi layer. The LUV' s heive a short 
circulating life span and are captured by the macrophages lining 
the liver sinusoids and to a smaller extent by circulating 
monocytes . The SUV's however have a longer circulating life 
span. They can escape via the sinusoids into the liver where 
they may be taken up by the hepatocytes. 
Liposome encapsulated macrophage activators have also been 
targetted to the macrophages in an attempt to activate these 
cells to a cytotoxic state in order to stop metastatic tumor 
growth m the lungs . Attempts have also been maae^  to target 
liposome encapsulated drugs to solid tumors. The literature 
availdCie on the uptake of liposomes'by the tumcsr ceils is 
however controversial. While some reports suggest consiceraiDle 
upt:i.Ke of liposomes by solid tumors, other reports have failed to 
indicate any preferential uptake of liposomes by tumor tissues. 
Gregorlardis suggested the possibility of enhancing tumor 
specific uptake by using liposomes .coated with monoclonal 
antibodies against tumor specific antigens . There is however 
little experimental validation of these possibilities. A degree 
of accumulation of tumor specific drugs has been attained in 
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tumors by a combination of heat sensitive liposomes and local 
hyperthermia. 
Liposomes have also been used as carriers for 
antifungal/ antiinfection adrugs to combat a variety of fungal/ 
infectious diseases. Some of the drugs used for the treatment of 
such diseases are highly toxic to the normal cells. Liposomes, 
when used as carriers for such drugs not only reduce their 
toxicity to normal cells, but also increase their therapeutic 
efficacy (26.27,28). 
Liposome also act as depots of drugs, for the sustained 
release of these drugs into circulation (29) . 
Earlier studies have demonstrated that upon injection: 
Large vesicles are cleared from the circulation more rapidly than 
the small ones. With vesicle populations of the same size, nega-
tively charged liposomes are cleared more rapidly, than the 
neutral liposomes, which are cleared more rapidly than positively 
charged liposomes. 
The interaction of liposomes with cells follows the follow-
ing four mechanisms: 
a) Adsorption to the cell surface 
b) Endocytosis 
c) Fusion and 
d) Lipid exchange 
Endocytosis and adsorption are however, the dominant 
mechanisms of liposome - cell interactions. 
The behaviour of liposomes in vivo can be considerably 
modulated by altering the properties, such as the compositions, 
surface charge, size and stability of the liposomes. 
Methods of conjugation: Sugar Protein conjugation. 
A number of hydroxy 1 groups are present on polysaccharides. 
They are however not sufficiently reactive to form covalent bonds 
with the protein molecules.Prior activation of the polysaccharide 
therefore becomes necessary. The activated polysaccharide is then 
allowed to react with the reactive residues of the proteins. 
Table III (30) gives a list of the various reactive residues on 
the proteins. 
The major methods of conjugation can be categorised in terms 
of the linkage formed between the ligand and the support. 
A20 bond formation: 
The reaction is carried out readily when the pclysaccharide 
to be linked contains an aromatic amine or diamine ( The amino 
derivative of polysaccharides can be prepared by first attaching 
a carboxy niethyl group by treatment with Chloroacetic acid and 
then reacting the carboxymethyi derivative with diamine 
dihyarochlorlde.) The aromatic amine or the diamine can then be 
converted into a diazonium sait by addition of Nitrous 
acid.{32)7he diazonium salt can conjugate directly tc the 
protein at alkaime pH (9.0).The reaction occurs primarily with 
Tyrosine, Histidine and Tryptophan residues of proteins. 
11 
12 
Polysaccharide-NH + N Ar - PoTysaccharide-NH-N-N-Ar 
2 2 
Polysaccharide-NH-N-N-Ar + Protein (Tyrosine) 
Polysaccharide-NH-N-N-protein. 
Care must be taken to minimise intraprotein and protein-
protein conjugation. This can be done by producing diazonium 
salts in the absence of the protein molecule. 
Formation of Peptide like bonds: 
The peptide bonds are formed by the nucleophilie'attack of 
the protein/ligand {amino, hydroxyl and thiol groups) on the 
activated polysaccharide carrier. Nucleophiles are most effective 
in their unprotonated forms at pH's above their pKa values. For 
coupling of proteins, however, an intermediate pH (7,5 - 8.5) and 
low temperatures (<4 C) are used to avoid denaturation. 
Activation by Cyanogen Bromide (CNBr) 
Cyanogen Bromide reacts rapidly with the•hydroxy 1 groups of 
polysaccharides to produce cyanate esters (the derivated matrix). 
This reaction proceeds most rapidly at alkaline pH (between 10 
and 12). These cyanate esters react most readily with tne 
primary amine groups on the proteins (Axen et ai 1967) ,(33) . It 
was first assumed that this reaction proceeds via the cyclic 
imidocarbonate intermediate, however, it has now oeen determined 
that in freshly activated polysaccharides 60-85^ of the total 
coupling capacity is due to the formation of cyanate esters. 
Imidocarbonates account for the rest, while carbanates are inert. 
Cyanate esters are stable at pH-4, while imidocarbonates are 
more stable in alkaline pH. The reactive species formed in the 
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activation step may be freeze dried and stored for long periods 
of time after acid treatment. 
A large part of the CNBr is hydrolysed to form Bromide, 
Cyanate and Cyanide in alkaline solution. Continuous removal of 
hydroxyl ions therefore occurs simultaneously with imidocarbonate 
formation. Usually the consumption of hydroxyl ions is 
compensated by the addition of alkali. 
After activation, coupling with the protein is carried out 
at slightly lower pH (-9). Variations in the coupling conditions 
may be introduced within certain limits of pH and temperature. 
The coupled product formed is quite stable within a wide 
range of pH. 
Carbonyldiimidazole Activation: 
Polysaccharide matrices may be activated using carbonylating 
agents such as N, N'-carbonyIdiImidazole (Hearn et al, 
1981),(34). Coupling achieved using this method Is comparable 
with that ot Cyanogen Bromide procedure, but it has several 
significant advantages. 
a) The reagent is more pleasant to handle than CNBr and the 
amount can be varied depending on the extent of activation 
required. 
b) A delay of upto six hours between activation and ligand 
coupling does not affect yield. 
c) Activated polysaccharide can be stored in dioxane and is 
stable under anhydrous conditions. 
d) The carbamate (urethane) derivatives obtained on coupling 
with amines are stable and uncharged. 
Carbodiimide-promoted condensation i 
Polysaccharides containing carboxyl groups can be activated 
using water soluble carbodi imides such as EDCI (1-ethy'L -3-( 
dimethylaminopropyl) - carbodi imide HCL) and similar reagents. 
Carbodi imide - catalysed amide formation appears to involve the 
formation of o-acyl derivatives which subsequently rearrange to 
acyl ureas or react with amino groups on ligands to give the 
corresponding amides. 
Carbodi imides can also be used successfully to couple carboxyl 
containing ligands (eg proteins) with carriers bearing amino or 
hydrazine groups. Carbodiimide reactions are frequently employed 
when a spacer ligand, often a linear alkylamine chain is 
introduced between the carrier and the ligand. Carbodi imides 
are versatile reagents that react not only with carboxylic and 
amino groups, but also with alcohols and other compounds having 
an active hydrogen. 
Alkylation or Arylation of ligand 
1. Oxirane based reactions: 
Bis-oxiranes (eg 1,4 - butanedioi digiyciaoxy et.'^ierj react 
reaaily at alkaline pH with the hyaroxyi groups of the 
polysaccharides to yield derivatives with long-cr.am h/aropniiic 
reactive oxirane. These reactive oxiranes then react with the 
nucleophilic groups on the proteins at alkaline pH (9-13), 
forming stable alkylamine linkages with the amino CTOUPS and 
thioether linkages with ligands containing thiol groups. 
The conjugates formed by this method are extremely stable 
U 
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thioether'linkages with ligands containing thiol groups. 
The conjugates formed by this method are extremely stable 
and they have a long hydrophilic spacer arm between th« protein 
and the polysaccharide. 
f OH +• CHi-CH-CH2.-0-CH2.CH2^CH3^CH^-0- Cf-^^- CH-CH^^ 
j 
I 
.O-CH,-Cri-CH^-0-(CHj.)- 0 - CH^- C H - C H j . 
OH 0 
Activation with divinyl sulfone: 
Vinyisuphony1 groups can be introduced into hydroxy 1 containing 
polymers by treatment with divinyIsulfone in alkali (Porath et al 
1975)(35). Subsequent reactions with the amino groups of the 
proteins can be performed at a somewhat lower pH. The reactioon 
proceeds rapidly. However some degree of cross lin:<ing cannot be 
avoided. 
Formation of Schiffs base linkages: 
Schiffs base (aidimine) linkages form between the c^rbonyl groups 
of the activated polysaccharides and the free amino groups on the 
ligand. 
Periodate Activation: 
Forms Schiffs base 1inkages.Polysaccharides can be activated by 
the oxidation of 1,2 dioi groups ( two hydroxy! groups on ad-
jacent Carbon atoms ). The cis-viscinal hydroxy 1 groups of the 
matrix are oxidised by Sodium metaperiodate (NaI04) to generate 
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aldehydic functions. These dialdehydes then react with the 
primary amino groups at a PH of around 4-6 to form Schiffs bases. 
Schiffs bases are relatively unstable specially at low pH.but 
they can be stabilised by reduction with NaBH4 (Sodium 
Borohydride) or NaBH3CN (Sodium cyanoborohydride) to form stable 
secondary amines. 
The reductive stabilisation of the intermediate Schiffs base 
is best achieved with NaBHSCN, since this reagent at a pH between 
6and 6.5 preferentially reduces Schiffs bases without reducing 
the aldehyde functions of. the polysaccharide, thereby driving the 
overall reaction to completion. 
The reaction mechanism is as follows: 
OH 
P- + NaI04 - P-CHO. 
OH 
P-CHO +RNH - P-CH=NR +H 0. 
2 2 
P-CH-NR + NaBH /NaBH CN = P-CH NHR. 
4 3 2 
Advantages: 
a) It is a rapid, safe, and simple method. 
b) A chemically stable ligand-sugar bond is formed. 
c) Periodate Is stable in aqueous media and exess reagent may be 
reaaily destroyed and removed by washing. 
d) Periodate-activated matrix is a stable intermediate which can^ 
be stored for weeks at 4 C without any appreciable loss of 
activity. 
Glutaraldehyde Activation : 
Glutaraldehyde is probably the most commonly used cross 
17 
linking agent. It can activate polysaccharides contjiining primary 
amino groups to yeild an active carbonyl derivative which will 
react with amino groups on the ligand. The linkages thus formed 
are resistant to extremes of pH and temperature. The mechanism of 
this reaction is, however, not well characterised. It seems 
unlikely that it is a straight forward reaction of the aldehyde 
and amino groups to form Schiffs bases. Conjugate addition of 
ligand amino groups to a, B-unsaturated oligomers, contained in 
commercial aqueous glutaraldehyde solutions, has been suggested 
as a probable reaction path. This would be consistant with the 
stability of glutaraldehyde-ligand linkages, which is greater 
than that of Schiffs base linkages. This would also be consistant 
with the lower reactivity observed when solution of freshly 
distilled glutaraldehyde are used. 
CHAPTER: 2 
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Object and Scope of Investigation: 
The object of our investigation is to study lysosomal 
storage diseases. These diseases are caused due to the 
accumulation. in the lysosomes, of certain metabolic interme-
diates. These intermediates accumulate due to the absence of the 
enzyme responsible for their degradation. The use of enzymes as 
therapeutic agents for the treatment of such disorders has long 
been recognised. It has however not met with much success due to 
the rapid bioinactivation of the injected enzyme as -a foreign 
protein. 
Information available suggests that glycoproteins are not 
easily degraded by proteolytic enzymes and are resistant to 
digestion . Also, most of the lysosomal enzymes are glycoproteins 
and are stable In the acidic milieu of the lysosomes (13). We 
therefore, Intend to study the stability of the native enzyme 
invivo, then modify it by attaching sugar residues on its 
surface. The stability of the modified enzyme will then be 
studied to check If giycosylatlon makes the enzyme more stable. 
The modified enzyme will then be used for the treatment of an 
artificially induced storage disease in mice using liposomes as a 
carrier for these enzymes. 
Here we present our results on the mode of uptake of horse 
raddlsh peroxidase (HRP) by the liver and its stability In vivo. 
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Materials and Methods: 
Horse Raddish Peroxidase was purchased from Hi Media 0-
dianisidene and Mannan were purchased from Sigma. All the other 
reagents were of AR grade. 
Animal experiments: 
Male Swiss Albino mice, weighing approximately 25-30 g were 
used throughout the experiment. Each mouse recieved a single 
intravenous injection coontaining 0.4 mg Horse Raddish Peroxidase 
in oaline. After various time intervals of 30 minutes, 1 hours, 
6hrs, 24hours groups of three animals each were sacrificed and 
their livers removed. Each tissue was washed with -0.956 NaCl 
solution and blotted on a filter paper. The tissue was 
homogenised in 10 mlPBS (0.25M, pH=7.4).An aliquot of the 
homogenate was kept aside and the rest of the homogene.te was 
fractinated by differential centrifugation into nuclear, 
mitochondrial/lysosomal and soluble fractions. Enzyme activity 
was then measured in the homogenate and the subcellular 
fractions. 
A group of three animals were taken as controls. They were 
not given any Injections. The animals were sacrificed, their 
livers taken out and processed. The tissue was then assayed for 
enzyme activity. 
Enzyme Assay: 
The tissue and the subcellular fractions were frozen and 
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then centrifuged and the clear supernatant taken for assay, 
Assay for Peroxidase : (Ref: Worthingtons Catalouge) 
Principle : 1) Peroxidase + H 0 - Compound (possibly a 
2 2 
ferric peroxide) 
2) Copound + AH (donor) - Peroxidase + H 0 + A 
2 2 
Step 1 is highly specific. Only H 2 methyl and ethyl 
20 
hydrogen peroxides combine with the enzyme - substrate compound. 
which in turn reacts with the hydrogen donor. 
The rate of decomposition of H 0 by peroxidase with o-
2 2 
dianisidine as Hydrogen donor is determined by measuring the rate 
of colour development at 460 nm. One unit of peroxidase activity 
is the amount of enzyme decompasing luM of H 0 per minute at the 
2 2 
recorded temperature. 
Reagents: 
Enzyme : Estimate Protein, dilute with buffer "o about 
0.5/ug protein/ml. 
Substrate: 1 mi of 305% H202 
(Stock) dilute to 100 ml with water. 
Diluted Dilute 1 ml of the stock H202 to 100 mi with 0.01 
solution : M PO buffer pH=6. 
4 
Prepared fresh before use 
Dye : 1% 0-dianiside in methanol 
(Keep in amber bottle) 
Procedure : 
Add 0.1 ml dye to 12 ml substrate. 
Set the spectrophotometer at 460 nm 
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Add the following to the test and the control 1 cm cuvettes 
Control Test 
Dye-substrate solution 2.9 ml 2.9 ml 
H 0 0.1 ml 
2 
Enzyme - 0.1 ml 
At time - 0 min, 0.1 ml of the enzyme was added and mixed 
rapidly. The change in absorbance ( at 460 nm) was recorded 
at 1 min intervals for 5 minutes. The curve should be linear. 
Determine Change in Absorbance/min. 
Specific Activity - Change in Absorbance at 460nm/min 
11.3 mg enzyme / ml Rxn mixture. 
Extinction Coeff -11.3uM. 
Mannan Inhibition Experiments: 
Injected 0.2ml (1.6 mgj Mannan into batches of tnree animals 
each. 0.4 mg of Peroxidase was injected into these animals ten 
minutes after the mannan injection. Animals were sacrificea 30 
minutes after the injection of HRP. The livers were removed and 
processed in the same way as described before. 
CHAPTER: 3 
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RESULTS AND DISCUSSION 
The rate of uptake and the rate of degradation of horse 
raddish peroxidase by the liver cells is presented in Fig A. This 
graph shows a maximum uptake of HRP by the liver one hour after 
its injection via the tail vein of the mice. After that, there is 
a rapid decrease in the amount of enzyme present in the liver to 
almost half its maximum value within six hours of injection, and 
zero percent activity twenty four hours after injection. 
The enzyme in its native form is therefore, not stable 
invivo and gets degraded rapidly within twenty four hours of 
injection. 
Peroxidase is a glycoprotein and it contains a number of 
mannosyl residues on its surface. The presence of mannose 
specific receptor on the surface of macropnages is well 
documented (15). .To check if HRP binds to these receptors and is 
taken in by receptor mediated enaocytotic mechanism. we did the 
manndn m.-^ -ibition experiments. yiannan competes with HRP for 
binding to the .mannosyl receptor. when mannan is giv-?n together 
or d l:tt-t.- joefore HRP, then the uptaxe or peroxiaase snould be 
reduced as compared to when HRP is given aione. ii ooth Dina to 
the same receptor. Batcnes or three animals each were sacrificed 
30 minutes, one hour, and six hours arter injection of HRP aione 
ana HRP together with mannan. A higniy signiricant decrease 
(Table IV) in the uptake of HRP was observea when it was given 
together with mannan and the animals were sacrificed 30minutes or 
one hour after injection. However, six hours after injection no 
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difference in the uptake between the two groups was observed. 
This can be explained by the fact that the mannosyl'receptor is a 
recycling kind of a receptor. It binds to the ligands at a high 
extracellular pH and high Ca ion concentration,and then releases 
them at the low lysosomal pH and Ca ion concentration. The 
receptor then recycles back to the surface ( ). This cycle takes 
about 30 minutes ( ). By six hours after injection the receptors 
are no longer blocked and they have recycled back to the surface. 
There is therefore no difference in the uptake of peroxidase with 
or without mannan, six hours after the enzyme was inje'Cted. 
Our work indicates that horse raddish peroxidase is taken up 
in vivo by the kupffer cells and this uptake is dependent on the 
mannose receptor as evidenced by the mannan inhibition. These 
results are m conformity with the in vitro work carried out by 
Lang, T and de Chasteilar, C. on Fluid phase ana mannose 
receptor-ineaiated uptake of horse raddisn peroxidase m mouse 
bone marrow derives macropnages (31). 
TABLES AND FIGURES 
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TABLE I: THE DEFECTS IN HUMAN LYSOSOMAL STORAGE DISEASES 
Disease Deficient hydrolase(s) 
Tay-Sachs disease, 
A variant. 
Sandhoff's disease 
Tay-Sachs disease, 
AB variant. 
Pompe's disease 
Metachromatic leuk-
odystrophy, late-
infantile form/ late 
onset form. 
Pseudodeficiency of 
arylsulfatase A 
Metachromatic leuk-
odystrophy ,vari ant 
form 
Mannosidosis 
Marateaux-Lamy 
syndrome,severe 
form. 
GMl gangliosidosis, 
infantile form. 
GMl gangliiosidosis, 
adult form. 
Galactosialidosis 
Hurler's disease 
Mucolipidosis II 
Mucolipidosis III 
(I-cell disease) 
Gaucher's disease, 
Types 1,2 and 3 
Hexosaminidase A f>-
jB -Hexosaminidases A and B 
B -Hexosaminidase activity 
' with GM2 ganglioside as 
substrate. 
w-Glucosidase. 
Arylsulfatase A. 
Arylsulfatase A. 
Arylsulfatase A with 
sulphatide as substrate 
ot-Mannosidase 
Arylsulfatase B. 
fe-Galactosidase. 
^ 
Galactosidase 
P -Galactosidase and 
membrane-bound neuraminidase 
QC -Iduronidase 
Several 
Several 
p -Glucocerebrosidase. 
From Tager, J.M. (1985) Trends Biochem. Sci. 10:324, 
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TABLE II: STRUCTURAL PROOPERTIES OF SOME HIGHLY PURIFIED ACID 
HYDROLASES. 
ENZYME 
Acid Phoshatase 
Deoxyribo-
nuclease II 
Ribonuclease II 
AryIsulphatase A 
exo-1,4 -gluco-
siidase 
Lysozyme 
B-N-acetyIgluco-
sammidase A 
B-N-acetyIgluco-
saminidase B 
B-Glucuronidase 
«G-L-Fucosidase 
Cathepsin B 1 
Cathepsin D 
SOURCE 
Human prostr. 
Pig spleen 
Human spleen 
Ox liver 
Beef liver 
Human urine 
Beef spleen 
Beef spleen 
Beef liver 
Rat epididym 
Beef spleen 
Human liver 
MOL.WT/SUBUNITS 
ate 
is 
102,000 
38,000 
18,000 
107,000 
107,000 
15,000 
140,000 
140,000 
280,000 
220,000, 
24.000 
45,000 
(2) 
(2) 
(4) 
(4) 
(4) 
GLYCOPROTEIN 
Yes. 
Yes. 
Yes. 
No. 
Yes. 
Yes. 
Yes. 
Yes. 
No. 
Yes. 
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TABLE III : REACTIVE RESIDUES OF PROTEINS (Srere and Uyeda 1976) 
-NH 
-SH 
-COOH 
fVoH 
H //^« 
-S-S-
<y-
CH -S-
-CH OH 
-Amino of L-Lysine (L-Lys) and 
N-terminus amino group. 
Thiol of L-cysteine (L-Cys) 
Carboxyl of L-aspartate (L-Asp) and 
L-gutamate (L-Glu) and C-terminus 
carboxyl group. 
Phenolic of tyrosine (L-Tyr; 
Guanidino of L-arginine (L-Arg) 
Imidazole of L-histidine (L-His) 
Bisulphide of L-cystine 
Indole of L-tryptophan (L-Trp) 
Thioether of L-methionine (L-Met) 
Hydroxy 1 of L-serine (L-Ser) and 
L-threonine (L-Thr) 
dl 
TABLE IV:EFFECT OF MANNAN ON THE UPTAKE OF HORSE RADDISH 
PEROXIDASE BY LIVER AT VARIOUS TIME INTERVALS 
0.4 mg of free HRP was injected into batches of three mice -via 
the tail vein and the uptake of Peroxidase was studied , when 
Peroxidase was injected without or 10 minutes (after Mannan 
injection (0.2 ml containing 1.6mg mannan) 
TIME HOMOGENATE 
% of activity injected 
MI TOCHONDRI, AL/LYSOSOMAL 
FRACTION: % of the 
activity In homogenate 
-M +M -M +M 
30 min 37.7 +11.4 13.9+2.1 
* * 
35.2 +4.1 16.8+3.4 
* * * 
One hour 56.2 +7.6 20.4+2.4 
* * * 
37.8 +0.3 17.4+2.9 
Six hours 21.2 +1.6 16.9+3.6 21.8 +1.9 21.7+6.2 
-M: (without Mannan) 
+iyi: (with Mannan) 
* 
* * * 
P<0.025 
P<0.005 
P<0.001 
FIG 1 
There is a maximum accumulation of Horse Raddish Peroxidase in 
the liver, one hour after injection. There after the enzyme is 
rapidly degraded within 24 hours. 
%0F INJECTED 
o 
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